A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty ® and COVID-19 mRNA Vaccine Moderna®

This study will provide crucial information about the efficacy and safety of the mRNA SARS-CoV-2 vaccines in HIV patients and organ transplant recipients. Furthermore, this project has the potential to pave the way for further platform trials in Switzerland.Trial registrationClinicalTrials.govNCT04805125. Registered on March 18, 2021
Source: Trials - Category: Research Source Type: clinical trials

Related Links:

The SARS-CoV-2 virus pandemic has put a massive struggle on health care systems. The only therapeutical option at the moment is vaccination. Viral mutation may reduce the efficacy of vaccines. We analyzed if a prophylactic immune cell activation using the bacterial extract Broncho Vaxom (BV) is beneficial during a coronavirus infection. To test our hypothesis we used a mouse coronavirus (MCoV) belonging to the same virus subfamily as SARS-CoV-2. BV was applied for 10 days before MCoV challenge. Viral load was significantly reduced in BV treated animals on day 4 and 10 compared to control (qPCR and histochemistry). BV treat...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Airway cell biology and immunopathology Source Type: research
World J Hepatol. 2021 Oct 27;13(10):1367-1377. doi: 10.4254/wjh.v13.i10.1367.ABSTRACTThe global pandemic of coronavirus disease 2019 (COVID-19) changed dramatically all priorities on medical society and created several challenges for clinicians caring for patients with liver diseases. We performed a comprehensive review about how COVID-19 can affect the liver, the influence of liver diseases on the risk of developing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 severity and also some strategies to overcome all the challenges clinicians have to face in the management of patients with liver disea...
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
World J Hepatol. 2021 Oct 27;13(10):1299-1315. doi: 10.4254/wjh.v13.i10.1299.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has profoundly impacted liver transplant (LT) activity across the world, with notable decreases in the number of donations and procedures in most Western countries, in particular throughout the first wave. The cumulative incidence of COVID-19 in LT recipients (with estimates ranging from 0.34% to 1.56%) appears to be at least comparable to that observed for the general population. Clinical and radiological features at presentation are also similar to non-transplant patients. The risk of deat...
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
World J Hepatol. 2021 Oct 27;13(10):1234-1268. doi: 10.4254/wjh.v13.i10.1234.ABSTRACTHepatitis C virus (HCV) is responsible for no less than 71 million people chronically infected and is one of the most frequent indications for liver transplantation worldwide. Despite direct-acting antiviral therapies fuel optimism in controlling HCV infections, there are several obstacles regarding treatment accessibility and reinfection continues to remain a possibility. Indeed, the majority of new HCV infections in developed countries occur in people who inject drugs and are more plausible to get reinfected. To achieve global epidemic c...
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
World J Hepatol. 2021 Oct 27;13(10):1367-1377. doi: 10.4254/wjh.v13.i10.1367.ABSTRACTThe global pandemic of coronavirus disease 2019 (COVID-19) changed dramatically all priorities on medical society and created several challenges for clinicians caring for patients with liver diseases. We performed a comprehensive review about how COVID-19 can affect the liver, the influence of liver diseases on the risk of developing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 severity and also some strategies to overcome all the challenges clinicians have to face in the management of patients with liver disea...
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
World J Hepatol. 2021 Oct 27;13(10):1299-1315. doi: 10.4254/wjh.v13.i10.1299.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has profoundly impacted liver transplant (LT) activity across the world, with notable decreases in the number of donations and procedures in most Western countries, in particular throughout the first wave. The cumulative incidence of COVID-19 in LT recipients (with estimates ranging from 0.34% to 1.56%) appears to be at least comparable to that observed for the general population. Clinical and radiological features at presentation are also similar to non-transplant patients. The risk of deat...
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
World J Hepatol. 2021 Oct 27;13(10):1234-1268. doi: 10.4254/wjh.v13.i10.1234.ABSTRACTHepatitis C virus (HCV) is responsible for no less than 71 million people chronically infected and is one of the most frequent indications for liver transplantation worldwide. Despite direct-acting antiviral therapies fuel optimism in controlling HCV infections, there are several obstacles regarding treatment accessibility and reinfection continues to remain a possibility. Indeed, the majority of new HCV infections in developed countries occur in people who inject drugs and are more plausible to get reinfected. To achieve global epidemic c...
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
World J Hepatol. 2021 Oct 27;13(10):1367-1377. doi: 10.4254/wjh.v13.i10.1367.ABSTRACTThe global pandemic of coronavirus disease 2019 (COVID-19) changed dramatically all priorities on medical society and created several challenges for clinicians caring for patients with liver diseases. We performed a comprehensive review about how COVID-19 can affect the liver, the influence of liver diseases on the risk of developing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 severity and also some strategies to overcome all the challenges clinicians have to face in the management of patients with liver disea...
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
World J Hepatol. 2021 Oct 27;13(10):1299-1315. doi: 10.4254/wjh.v13.i10.1299.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has profoundly impacted liver transplant (LT) activity across the world, with notable decreases in the number of donations and procedures in most Western countries, in particular throughout the first wave. The cumulative incidence of COVID-19 in LT recipients (with estimates ranging from 0.34% to 1.56%) appears to be at least comparable to that observed for the general population. Clinical and radiological features at presentation are also similar to non-transplant patients. The risk of deat...
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
World J Hepatol. 2021 Oct 27;13(10):1234-1268. doi: 10.4254/wjh.v13.i10.1234.ABSTRACTHepatitis C virus (HCV) is responsible for no less than 71 million people chronically infected and is one of the most frequent indications for liver transplantation worldwide. Despite direct-acting antiviral therapies fuel optimism in controlling HCV infections, there are several obstacles regarding treatment accessibility and reinfection continues to remain a possibility. Indeed, the majority of new HCV infections in developed countries occur in people who inject drugs and are more plausible to get reinfected. To achieve global epidemic c...
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
More News: China Health | Clinical Trials | Coronavirus | COVID-19 | Pandemics | Pfizer | Research | SARS | Science | Statistics | Study | Switzerland Health | Transplants | Vaccines